Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05153239 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
A Phase 3 study of Relapsed Small Cell Lung Cancer, sponsored by PharmaMar.
- Active
- Registry status
- Phase 3
- Development phase
- 705
- Enrollment target
- 20
- Study locations
NCT05153239: Active Phase 3 study of Relapsed Small Cell Lung Cancer, sponsored by PharmaMar.
NCT05153239 is a Phase 3 study of Relapsed Small Cell Lung Cancer that is active but no longer recruiting, run by PharmaMar. The registered enrollment target is 705 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05153239, a Phase 3 study of Relapsed Small Cell Lung Cancer, is active but no longer recruiting, sponsored by PharmaMar.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 705 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
Primary Outcome
Overall survival (OS) will be calculated from the date of randomization to the date of death or last contact (in this case, survival will be censored on that date).
Conditions Studied
Interventions
- DRUG Irinotecan
- DRUG Topotecan
- DRUG Lurbinectedin
Study Locations (20)
Florida
- Florida Cancer Specialists - South - Fort Myers
- Florida Cancer Specialists - North - St. Petersburg
- Florida Cancer Specialists - Panhandle - Tallahassee
- Florida Cancer Specialists - East - West Palm Beach
Nebraska
- Oncology Hematology West, PC (Grand Island) - Grand Island
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Omaha
Victoria
- BRICC - Ballarat Health Services - Ballarat Central
- Box Hill Hospital Eastern Health Clinical School - Box Hill
Other
- Northern Beaches Hospital - Frenchs Forest
- Gosford Hospital GH - Central Coast Cancer Centre - Gosford
Arizona
- Ironwood Cancer & Research Centers - Chandler
Arkansas
- Genesis Cancer and Blood - Hot Springs
Illinois
- Duly Health and Care - Joliet
Kentucky
- Norton Cancer Institue, Downtown - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 705 participants |
| Start Date | 2022-07-22 |
| Est. Completion | 2026-04 |
| Phase | Phase 3 |
What the registry record for NCT05153239 still lists
NCT05153239 is an interventional study that assigns participants to a tested intervention. The registered 705 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 1 condition, with Relapsed Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Irinotecan is the first listed.
NCT05153239 names 20 study sites across 14 states, led by Florida, Nebraska, Victoria.
Frequently Asked Questions
What is clinical trial NCT05153239 about?
NCT05153239 is a clinical study titled "Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)". Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topoteca...
What is the current status of trial NCT05153239?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 705 participants. The study started on 2022-07-22. Estimated completion is 2026-04.
What conditions does trial NCT05153239 study?
This clinical trial studies the following conditions: Relapsed Small Cell Lung Cancer.
What interventions are being tested in trial NCT05153239?
The interventions under investigation include: Irinotecan (DRUG), Topotecan (DRUG), Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT05153239?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05153239 being conducted?
This trial has 20 study locations across Arizona, Arkansas, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05153239's enrollment target sits among peer trials
705 505th of 2000 higher than 1,495 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI